Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Bought by Barclays PLC

Barclays PLC boosted its position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 292.6% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 57,599 shares of the company’s stock after purchasing an additional 42,926 shares during the quarter. Barclays PLC owned about 0.11% of Zevra Therapeutics worth $399,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC boosted its position in shares of Zevra Therapeutics by 282,687.5% during the third quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after buying an additional 2,312,384 shares during the period. State Street Corp raised its stake in Zevra Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 772,825 shares of the company’s stock valued at $5,363,000 after acquiring an additional 52,966 shares in the last quarter. Stonepine Capital Management LLC acquired a new position in Zevra Therapeutics during the 3rd quarter worth $4,858,000. Vestal Point Capital LP bought a new position in shares of Zevra Therapeutics in the third quarter worth $3,644,000. Finally, Retirement Planning Co of New England Inc. raised its stake in shares of Zevra Therapeutics by 6.5% during the second quarter. Retirement Planning Co of New England Inc. now owns 458,300 shares of the company’s stock valued at $2,246,000 after purchasing an additional 28,107 shares in the last quarter. 35.03% of the stock is owned by institutional investors and hedge funds.

Zevra Therapeutics Price Performance

Shares of NASDAQ:ZVRA opened at $8.59 on Friday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The company has a market capitalization of $458.50 million, a PE ratio of -4.36 and a beta of 1.97. The stock has a fifty day moving average of $8.77 and a 200-day moving average of $7.48. Zevra Therapeutics, Inc. has a one year low of $4.20 and a one year high of $9.76.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The company had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. During the same period in the prior year, the company earned ($0.40) earnings per share. As a group, equities analysts anticipate that Zevra Therapeutics, Inc. will post -1.96 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on ZVRA. JMP Securities assumed coverage on shares of Zevra Therapeutics in a research report on Tuesday, September 24th. They issued an “outperform” rating and a $17.00 target price for the company. Canaccord Genuity Group lowered their price objective on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, November 20th. Guggenheim initiated coverage on Zevra Therapeutics in a research report on Monday, October 7th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Roth Mkm upped their price objective on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $21.00.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.